Refine
Has Fulltext
- yes (6)
Is part of the Bibliography
- yes (6)
Document Type
- Journal article (6)
Language
- English (6)
Keywords
- GFAP (2)
- cognitive impairment (2)
- heart failure (2)
- myocardial infarction (2)
- neurofilament light chain (2)
- Alzheimer’s dementia (1)
- B cells (1)
- Brain atrophy (1)
- CIED malfunction; pacemaker (PM) (1)
- Chronic heart failure (1)
- Cognitive decline (1)
- Glial fibrillary acidic protein (1)
- MRI (1)
- Memory dysfunction (1)
- NfL (1)
- STEMI (1)
- age (1)
- antibodies (1)
- aortic valve stenosis (1)
- atrial fibrillation (1)
- battery depletion (1)
- cardiac arrest (1)
- cardiac implantable electronic devices (CIED) (1)
- cardiac magnetic resonance imaging (1)
- cardiac resynchronization therapy (CRT) (1)
- coronary artery disease (1)
- dementia (1)
- eculizumab (1)
- glial damage (1)
- glial fibrillary acidic protein (1)
- hypertension (1)
- implantable cardioverter defibrillator (ICD) (1)
- inebilizumab (1)
- infarction size (1)
- neuroinflammation (1)
- neuromyelitis optica spectrum disorders (1)
- phosphorylated tau protein (1)
- radiotherapy (RT) (1)
- ravulizumab (1)
- renal function (1)
- satralizumab (1)
- tocilizumab (1)
- ublituximab (1)
Institute
- Medizinische Klinik und Poliklinik I (6)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (3)
- Neurologische Klinik und Poliklinik (3)
- Institut für diagnostische und interventionelle Neuroradiologie (ehem. Abteilung für Neuroradiologie) (2)
- Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Virologie und Immunbiologie (1)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (1)
- Klinik und Poliklinik für Strahlentherapie (1)
Sonstige beteiligte Institutionen
The first description of neuromyelitis optica by Eugène Devic and Fernand Gault dates back to the 19th century, but only the discovery of aquaporin-4 autoantibodies in a major subset of affected patients in 2004 led to a fundamentally revised disease concept: Neuromyelits optica spectrum disorders (NMOSD) are now considered autoantibody-mediated autoimmune diseases, bringing the pivotal pathogenetic role of B cells and plasma cells into focus. Not long ago, there was no approved medication for this deleterious disease and off-label therapies were the only treatment options for affected patients. Within the last years, there has been a tremendous development of novel therapies with diverse treatment strategies: immunosuppression, B cell depletion, complement factor antagonism and interleukin-6 receptor blockage were shown to be effective and promising therapeutic interventions. This has led to the long-expected official approval of eculizumab in 2019 and inebilizumab in 2020. In this article, we review current pathogenetic concepts in NMOSD with a focus on the role of B cells and autoantibodies as major contributors to the propagation of these diseases. Lastly, by highlighting promising experimental and future treatment options, we aim to round up the current state of knowledge on the therapeutic arsenal in NMOSD.